Drawing on clinical and registry partnerships from around the globe, TriNetX provides real-world data that combines histology, genomic variants, and other biomarkers with treatment, line change, and survival records, so your research can run deeper.

Staging, biomarkers, and more from CTR-curated registries 

Our partnerships with cancer registries around the world let us bring together a large and growing volume of primary site, histology, staging, and biomarker data.

Genomic data from hospitals and external laboratories

We source mutation and variant data from a cross section of genomic laboratories, for richer genetic profiles on a more diverse patient population.

Granular EHR and lab data, pre- and post-cancer

Detailed EHR data and lab results, from before diagnosis and after treatment, open new avenues of research into risks, treatment planning, and prognoses. 

Academic and community hospitals
from around the world

In our data, you’ll find the latest immunologic treatments for rare cancers, along with chemo line progressions for tumors that are all too common. 

Curated Oncology Datasets

Sourced from centers of excellence in the United States, our oncology datasets combine structured EMR data, registry data, lab results, genomic variants, and mortality records from the Social Security Administration and private obituaries.

Our data models puts cancer in context. Unique identifiers for each patient, visit, and cancer diagnosis let you bring together the variables you need quickly.

Our datasets for breast and lung cancer are available to license now. We are building equally rich datasets for additional indications. Connect with us to learn about our roadmap.

Breast Cancer Dataset

Patients

Median age at diagnosis

Received hormone therapy as their first treatment course

Received immunotherapy as first course of therapy

Received beam radiation

Black or African-American patients

HER2+ patients

HR- patients

Lung Cancer Dataset

Patients

Median age at diagnosis

Received immunotherapy as their first treatment course

Received beam radiation

Non-small cell lung cancer patients

Small cell lung cancer patients

Current or prior smoker

Patients with EGFR mutation